Return to Publications  |  Return to CINJ Home
Rutgers Cancer Institute of New Jersey's Cancer Connection, April 2015
Donate NowThe latest news on research, treatment, prevention and education from the
state's only National Cancer Institute-designated Comprehensive Cancer Center
Director of Rutgers Cancer Institute of New Jersey Named to the NJBiz "Power 50 Health Care" List

 

DiPaola

Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, was ranked #27 on this year's NJBIZ "Power 50 Health Care" list. This annual list ranks the best of the best in health care in New Jersey. View the profile on Dr. DiPaola and all of those named to this year's list.

Meridian Health Partners with Rutgers Cancer Institute of New Jersey to Expand Personalized Treatment Offerings to Patients

 

DNA

Rutgers Cancer Institute of New Jersey is joining forces with its System Partner Meridian Health in offering patients with rare forms of cancer or with cancer that no longer responds to standard treatment, access to its precision medicine clinical trial close to home. The research will use a process known as genomic analysis to identify abnormal changes in the genetic make-up (DNA) of the cancer. The clinical trial is part of the 'precision medicine' initiative at the Cancer Institute of New Jersey, which aims to tailor or 'personalize' cancer treatment for patients.Learn more

Research Shows Gene Removal May Aid Melanoma Treatment

 

Mehnert and White

There are nearly 10,000 melanoma deaths in the U.S. each year, and while treatment advances have been made, a majority of patients will die from their disease. Building on these advances, Rutgers Cancer Institute of New Jersey investigators Janice M. Mehnert, MD, medical oncologist at the Cancer Institute and associate professor of medicine at Rutgers Robert Wood Johnson Medical School and Eileen White, PhD, associate director for basic science at the Cancer Institute and distinguished professor of molecular biology and biochemistry at Rutgers School of Arts and Sciences, have demonstrated that removal of a gene involved in the cellular self-cannibalization process of autophagy could provide therapeutic benefit to patients with melanoma.Learn more

Study Shows Favorable 15-Year Survival Outcomes for Older Prostate Cancer Patients with Low-Risk Disease

 

transitions

Results from a population-based study from investigators at Rutgers Cancer Institute of New Jersey show favorable survival outcomes among patients with low-risk prostate cancer treated with conservative management initially. The study, which appears in the current online edition of European Urology (doi: 10.1016/j.eururo.2015.03.021) and is led by Grace Lu-Yao, PhD, MPH, cancer epidemiologist at the Cancer Institute and professor of medicine at Rutgers Robert Wood Johnson Medical School, looked at data for men 65 and older and extends previous data examination by the team an additional five years.Learn more

Rutgers Cancer Institute of New Jersey Offers Clinical Trial for Solid Tumors with Novel Small Molecule Agent

 

transitions

Rutgers Cancer Institute of New Jersey is offering a clinical trial examining the investigational treatment known as ONC201 in patients with solid tumors whose cancer no longer responds to standard therapy. As principal investigator Mark Stein, MD, member of the Phase I/Investigational Therapeutics Program at the Cancer Institute and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School tells us, prior research on the study drug suggests that it may be capable of turning off proteins that maintain tumor growth and and may help kill cancer cells while sparing normal ones.Learn more

            Rutgers Cancer Institute of New Jersey                                          NCI logo 

Office of Communications         ·         www.cinj.org        ·        732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List